Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and cardiovascular surgical applications..

Novanta Inc.（纳斯达克股票代码：NOVT）（“Novanta”或“公司”）是医疗和先进技术设备制造商值得信赖的技术合作伙伴，今日宣布已完成从Arlington Capital Partners手中收购Riverpoint Medical（“Riverpoint Medical”或“Riverpoint”）。Riverpoint是高增长微创手术耗材领域的品类领导者，产品包括用于运动医学、创伤和心血管外科应用的先进手术光纤及相关技术。

“Riverpoint Medical is a market-leading, high-growth surgical consumables business growing revenue and cash flow at twice Novanta's rate, and the acquisition is expected to double Novanta's recurring medical consumables revenue to roughly $300 million while pushing medical end-market exposure to 60% of total revenue,” said Matthijs Glastra, Novanta’s Chair & Chief Executive Officer.

Novanta董事长兼首席执行官Matthijs Glastra表示：“Riverpoint Medical是一家市场领先、高增长的手术耗材企业，其收入和现金流增速均为Novanta的两倍。此次收购预计将使Novanta的经常性医疗耗材收入翻倍，达到约3亿美元，同时使医疗终端市场的收入占比提升至总收入的60%。”

“Beyond the top-line boost, we believe the deal unlocks a $2 billion incremental addressable market through shared OEM customer relationships and strengthens Novanta’s regional, FDA-registered manufacturing footprint, positioning the overall company for accelerated, higher-margin growth.”.

“除了提升营收之外，我们相信该交易通过共享原始设备制造商（OEM）客户关系，解锁了20亿美元的增量可触达市场，并增强了Novanta在区域层面的美国食品药品监督管理局（FDA）注册制造布局，从而使公司整体处于加速实现更高利润率增长的有利地位。”

The transaction is expected to generate a high single-digit return on invested capital by year three, achieve the Company’s return hurdle rate by year five, and be immediately accretive to Novanta’s organic growth, adjusted gross margins, adjusted EBITDA growth and margins, and cash flows. The acquisition is also expected to contribute $0.18 to $0.25 of adjusted earnings per share (“EPS”) in 2027, the first full year after the close, with additional detail on the impact to Novanta’s 2026 financials to be provided on the upcoming second quarter earnings call.

预计该交易在第三年将产生较高的个位数投入资本回报率，在第五年达到公司的回报门槛率，并立即对诺万塔（Novanta）的有机增长、调整后毛利率、调整后息税折旧摊销前利润（EBITDA）的增长及利润率以及现金流产生增厚效应。预计此次收购将在交易完成后的第一个完整年度（2027年）为调整后每股收益（“EPS”）贡献0.18至0.25美元，关于对诺万塔2026年财务业绩影响的更多细节将在即将到来的第二季度财报电话会议上提供。

Riverpoint Medical will be reported under Novanta’s Medical Solutions operating segment..

Riverpoint Medical 将在 Novanta 的医疗解决方案运营分部下报告。

Use of Non-GAAP Financial Measures

非公认会计准则财务指标的使用

The non-GAAP financial measures referenced in this press release include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Margin, and Adjusted Diluted EPS. A reconciliation of these forward-looking non-GAAP measures to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including the final purchase price allocation, amortization of acquired intangibles, and other acquisition-related items not available prior to closing.

本新闻稿中提及的非公认会计准则（Non-GAAP）财务指标包括调整后息税折旧摊销前利润（Adjusted EBITDA）、调整后息税折旧摊销前利润率、调整后毛利率以及调整后稀释每股收益。由于在预测和量化进行此类调节所需的某些金额方面存在固有的困难，包括最终购买价格分摊、已收购无形资产的摊销以及在交易完成前无法获取的其他与收购相关的项目，因此未提供这些前瞻性非公认会计准则财务指标与最直接可比的公认会计准则（GAAP）财务指标之间的调节表。

For definitions of these measures and reconciliations of historical non-GAAP results, refer to Novanta's most recent filings with the Securities and Exchange Commission..

有关这些指标的定义及历史非公认会计准则结果的调节表，请参阅诺凡塔公司最近向美国证券交易委员会提交的文件。

Safe Harbor and Forward-Looking Information

安全港声明与前瞻性信息

Certain statements in this news release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “will,” “plan,” “aim,” and other similar expressions.

本新闻稿中的某些陈述属于1995年《私人证券诉讼改革法案》所定义的“前瞻性陈述”，并基于当前预期和假设，这些预期和假设受风险和不确定性的影响。本新闻稿中所有与历史事实无关的陈述均应视为前瞻性陈述，通常通过“期望”、“打算”、“预计”、“估计”、“相信”、“未来”、“目标”、“可能”、“应当”、“可以”、“将”、“计划”、“旨在”及其他类似表述来识别。

These forward-looking statements include, but are not limited to, the statement of Mr. Glastra in this press release; statements regarding the acquisition of Riverpoint Medical, the anticipated benefits and synergies of the transaction, our ability to successfully integrate Riverpoint Medical, and our ability to implement our plans, forecasts and other expectations with respect to Riverpoint Medical’s business after the completion of the acquisition, expected financial performance and impact, financial position and financial measures and metrics, including expectations regarding accretion, revenue growth, margins, cash flows, return on capital and adjusted earnings per share, our financial outlook for Novanta, Riverpoint Medical and the combined companies, expectations for future growth and prospects, expectations for strategies and business models, and other statements that are not historical facts..

这些前瞻性陈述包括但不限于本新闻稿中Glastra先生的陈述；有关收购Riverpoint Medical的陈述、交易预期的效益和协同效应、我们成功整合Riverpoint Medical的能力，以及在收购完成后就Riverpoint Medical业务实施我们的计划、预测和其他期望的能力；预期财务表现及影响、财务状况和财务指标与度量，包括对每股收益增厚、收入增长、利润率、现金流、资本回报率和调整后每股收益的预期；我们对Novanta、Riverpoint Medical及合并后公司的财务展望；对未来增长和前景的预期；对战略和商业模式的预期；以及其他非历史事实的陈述。

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause future expectations and actions and actual results to differ materially from those contained in the forward-looking statements. Our future expectations and actions and actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: the possibility that any of the anticipated benefits or synergies of the transaction may not be realized; the risk that the business of Riverpoint Medical may not be integrated successfully; and other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition that are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission.

这些前瞻性陈述既非承诺也非保证，而是涉及风险和不确定性，可能导致未来预期、行动及实际结果与前瞻性陈述中所载内容存在重大差异。由于各种重要因素，我们的未来预期、行动及实际结果可能与这些前瞻性陈述中的预期存在重大差异，包括但不限于以下因素：交易预期的任何利益或协同效应可能无法实现的风险；Riverpoint Medical 的业务可能无法成功整合的风险；以及可能影响本陈述所述事件结果、并可能影响公司经营业绩和财务状况的其他重要风险因素，这些因素在我们截至2025年12月31日财政年度的10-K表格年度报告第一部分第1A项中进行了讨论，并由我们随后向美国证券交易委员会提交的文件予以更新。

Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. Undue reliance should not be placed on these statements, which are only effective as of the date of this news release. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this news release except as required by law..

此类陈述基于本公司的信念和假设以及本公司目前可获得的信息。不应过度依赖这些陈述，它们仅在本新闻稿发布之日有效。除法律要求外，本公司不承担因本新闻稿发布之日后发生的发展而公开更新或修订任何此类前瞻性陈述的义务。

About Riverpoint Medical

关于Riverpoint Medical

Riverpoint Medical is a category leader in high-growth minimally invasive surgical consumables, designing and manufacturing IP-protected, private-label products for leading medical OEM customers. Riverpoint’s portfolio includes suture anchors, implantable materials, sutures, and surgical instruments, primarily serving sports medicine and cardiovascular surgery applications.

Riverpoint Medical 是高增长微创手术耗材领域的品类领导者，为领先的医疗原始设备制造商（OEM）客户设计和制造受知识产权保护的非自有品牌产品。Riverpoint 的产品组合包括缝合锚钉、植入材料、缝线和手术器械，主要服务于运动医学和心血管外科应用领域。

The company’s differentiated position is built on proprietary material science and coating technologies, including osteoconductive materials and coatings, and its ability to own the 510(k) clearance process end-to-end for its customers. Riverpoint is headquartered in Portland, Oregon U.S.A., with manufacturing operations in Portland, Oregon and San Jose, Costa Rica.

该公司的差异化地位建立在专有的材料科学和涂层技术之上，包括骨传导材料和涂层，以及为其客户提供端到端510(k)许可流程的能力。Riverpoint总部位于美国俄勒冈州波特兰市，在俄勒冈州波特兰和哥斯达黎加圣何塞设有制造业务。

For more information, visit www.rpmed.com..

欲了解更多信息，请访问 www.rpmed.com。

About Novanta

关于诺万塔

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges.

Novanta 是全球领先的核心技术解决方案供应商，为医疗、生命科学和先进工业领域的原始设备制造商提供竞争优势。我们将我们在精准医疗、精密制造、机器人与自动化以及先进手术领域的深厚专有技术和能力，与解决复杂技术挑战的经证实的能力相结合。

This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success.

这使得诺凡特能够开发专有技术解决方案，提供极高的精度和性能，以满足客户苛刻的应用需求。推动我们增长的核心力量是一支充满创新精神的专业团队，他们共同致力于创新、践行诺凡特增长体系，并助力客户取得成功。

Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”.

Novanta的普通股在纳斯达克上市，股票代码为“NOVT”。

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com. Media Relations at mediarelations@novanta.com.

更多关于诺万塔的信息，请访问公司网站 www.novanta.com。如需更多信息，请联系诺万塔投资者关系部门，电话：(781) 266-5137，邮箱：InvestorRelations@novanta.com。媒体联络邮箱：mediarelations@novanta.com。

About Arlington Capital Partners

关于阿灵顿资本伙伴公司

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. Focused on the healthcare, aerospace and defense, and government services and technology sectors, the Firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities.

阿灵顿资本合伙公司（Arlington Capital Partners）是一家位于华盛顿特区地区的私人投资公司，专注于政府监管行业。该公司聚焦于医疗保健、航空航天与国防，以及政府服务与技术领域，与创始人和企业家合作，打造符合国家战略优先事项的重要平台。

Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness, and reduce costs. Since inception in 1999, Arlington has invested in over 200 companies and raised over $14 billion in committed capital. The Firm is currently investing out of its $6 billion Fund VII.

阿灵顿在具有高进入壁垒的市场中运营，寻求与这些行业中能够挽救生命、提高效能并降低成本的组织建立合作伙伴关系。自1999年成立以来，阿灵顿已投资200多家公司，募集承诺资本超过140亿美元。目前，该公司正通过其规模达60亿美元的第七期基金进行投资。

For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn..

欲了解更多信息，请访问阿灵顿官网 www.arlingtoncap.com，并在领英上关注阿灵顿。

Contacts

联系人

Novanta Investor Relations

Novanta 投资者关系

(781) 266-5137

(781) 266-5137

InvestorRelations@novanta.com

投资者关系@novanta.com

Media Relations

媒体关系

mediarelations@novanta.com

mediarelations@novanta.com

Source: businesswire.com

来源：businesswire.com